BioSpace News Archive

Trinity Life Sciences, a leader in global life sciences solutions, introduces a new turnkey stakeholder insight research tool that evaluates the impact of COVID-19 on patient management and load, prescribing and compliance behaviors and sales detailing relative to pre-COVID times

Fern Health, a digital health company pioneering virtual musculoskeletal pain programs through employers, today announced the appointment of Hewett Chiu as Chief Operating Officer.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin),

Swittons, a P360 company, today announced that its complete lineup of customizable IoT powered devices now includes integration with Microsoft Teams.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President & Chief Executive Officer, will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23 at 10:30 am ET.

Fulgent Genetics has received Emergency Use Authorization from the FDA to provide at-home testing services for SARS-CoV-2, the virus that causes COVID-19

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the closing of its initial public offering of 16,560,000 shares of common stock,

Actinium Pharmaceuticals, Inc. announced that it intends to offer and sell shares of its common stock in a public offering.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Javier Rodriguez has been appointed to the company’s Board of Directors. Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a Fortune 500 company providing healthcare services to kidney disease patients throughout the United States and internationally that strives to improve patients’ quality of life through clinical innovation and integrated, personalized care

Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Alison Lawton has chosen to step down from her position as President and Chief Executive Officer in order to return to the United Kingdom and attend to an unexpected family health matter.